Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to 5-FU
Related studies linked through entity extraction aliases.
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
First-line Therapy in Metastatic PDAC
- Status
- UNKNOWN
- Phase
- PHASE2
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
- Status
- WITHDRAWN
- Phase
- PHASE2
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
- Status
- COMPLETED
- Phase
- PHASE3
Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
- Status
- COMPLETED
- Phase
- PHASE2
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
- Status
- TERMINATED
- Phase
- PHASE2
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
- Status
- COMPLETED
- Phase
- PHASE2
Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
- Status
- COMPLETED
- Phase
- PHASE3
Nordic Pancreatic Cancer Trial (NorPACT) - 1
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3